Please login to the form below

Not currently logged in
Email:
Password:

tralokinumab

This page shows the latest tralokinumab news and features for those working in and with pharma, biotech and healthcare.

AZ’s Fasenra hit by COPD trial failure

AZ’s Fasenra hit by COPD trial failure

IL-13 inhibitor tralokinumab has been abandoned after three failed late-stage trials, however, while AZ also has an Amgen-partnered thymic stromal lymphopoietin (TSLP) targeting antibody - tezepelumab - in phase III

Latest news

More from news
Approximately 4 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Leo has its eyes on the prize Leo has its eyes on the prize

    Its landmark partnership with AstraZeneca and the launch of Kyntheum, the fully-human monoclonal antibody targeting psoriasis, and the phase III hope of tralokinumab for atopic dermatitis are part of an

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    Out-partnering deals included the $1.1bn licence to LEO for tralokinumab in skin diseases and the $1bn divestment to Pfizer of its late-stage small molecule anti-infective business.

  • Deal Watch July 2016 Deal Watch July 2016

    AstraZeneca is developing tralokinumab for severe asthma, where it is in phase III development, and has recently completed a phase IIb study in patients with atopic dermatitis. ... Acquisition. 1, 530. AstraZeneca/ Leo Pharma. Tralokinumab (anti-IL-13)

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics